{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:15:20Z","timestamp":1790928920400,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience Letters"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1016\/j.neulet.2008.05.067","type":"journal-article","created":{"date-parts":[[2008,6,4]],"date-time":"2008-06-04T12:05:03Z","timestamp":1212581103000},"page":"97-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Pramipexole has astrocyte-mediated neuroprotective effects against lactacystin toxicity"],"prefix":"10.1016","volume":"440","author":[{"given":"Keiko","family":"Imamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Takeshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Nakaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neulet.2008.05.067_bib1","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1056\/NEJM199810083391506","article-title":"Parkinson's disease. First of two parts","volume":"339","author":"Lang","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neulet.2008.05.067_bib2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0166-4328(02)00180-8","article-title":"Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats","volume":"136","author":"Alam","year":"2002","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neulet.2008.05.067_bib3","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/81834","article-title":"Chronic systemic pesticide exposure reproduces features of Parkinson's disease","volume":"3","author":"Betarbet","year":"2000","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neulet.2008.05.067_bib4","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.1212\/WNL.47.6_Suppl_3.153S","article-title":"The etiology of Parkinson's disease with emphasis on the MPTP story","volume":"47","author":"Langston","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.neulet.2008.05.067_bib5","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1124\/jpet.105.092312","article-title":"Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-l-propylamino-benzathiazole dihydrochloride]","volume":"316","author":"Danzeisen","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neulet.2008.05.067_bib6","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/j.1471-4159.2004.02804.x","article-title":"Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms","volume":"91","author":"Gu","year":"2004","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neulet.2008.05.067_bib7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0014-2999(01)00902-5","article-title":"Release and aggregation of cytochrome c and alpha-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole","volume":"417","author":"Kakimura","year":"2001","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neulet.2008.05.067_bib8","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1124\/mol.54.6.1046","article-title":"Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells","volume":"54","author":"Kitamura","year":"1998","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neulet.2008.05.067_bib9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.expneurol.2004.06.021","article-title":"Involvement of dopamine D(2)\/D(3) receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells","volume":"190","author":"Presgraves","year":"2004","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neulet.2008.05.067_bib10","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00210-005-0025-2","article-title":"Pramipexole protects against H2O2-induced PC12 cell death","volume":"372","author":"Fujita","year":"2006","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.neulet.2008.05.067_bib11","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejphar.2006.11.011","article-title":"Novel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous dopamine-mediated excitotoxicity","volume":"557","author":"Izumi","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neulet.2008.05.067_bib12","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1096\/fj.05-4748fje","article-title":"Patch clamp reveals powerful blockade of the mitochondrial permeability transition pore by the D2-receptor agonist pramipexole","volume":"20","author":"Sayeed","year":"2006","journal-title":"FASEB J."},{"key":"10.1016\/j.neulet.2008.05.067_bib13","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1212\/WNL.66.10_suppl_4.S37","article-title":"Proteasomal dysfunction in sporadic Parkinson's disease","volume":"66","author":"McNaught","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.neulet.2008.05.067_bib14","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/33416","article-title":"Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism","volume":"392","author":"Kitada","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.neulet.2008.05.067_bib15","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/26652","article-title":"The ubiquitin pathway in Parkinson's disease","volume":"395","author":"Leroy","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.neulet.2008.05.067_bib16","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/ana.20936","article-title":"Proteasome inhibitor-induced model of Parkinson's disease","volume":"60","author":"McNaught","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neulet.2008.05.067_bib17","doi-asserted-by":"crossref","first-page":"8955","DOI":"10.1523\/JNEUROSCI.23-26-08955.2003","article-title":"Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition","volume":"23","author":"Fornai","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neulet.2008.05.067_bib18","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0278-5846(03)00019-8","article-title":"Apoptosis and Parkinson's disease","volume":"27","author":"Lev","year":"2003","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neulet.2008.05.067_bib19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0165-0270(96)00002-7","article-title":"Standardized methods to bioassay neurotrophic factors for dopaminergic neurons","volume":"67","author":"Takeshima","year":"1996","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.neulet.2008.05.067_bib20","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/jnr.490390404","article-title":"Beta\/A4-evoked degeneration of differentiated SH-SY5Y human neuroblastoma cells","volume":"39","author":"Lambert","year":"1994","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.neulet.2008.05.067_bib21","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.bbrc.2005.11.095","article-title":"Novel cytoprotective mechanism of anti-parkinsonian drug deprenyl: PI3K and Nrf2-derived induction of antioxidative proteins","volume":"339","author":"Nakaso","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neulet.2008.05.067_bib22","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/jnr.21021","article-title":"d-beta-hydroxybutyrate protects dopaminergic SH-SY5Y cells in a rotenone model of Parkinson's disease","volume":"84","author":"Imamura","year":"2006","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.neulet.2008.05.067_bib23","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1385-299X(97)00045-7","article-title":"A rapid and sensitive assay for measuring mitochondrial metabolic activity in isolated neural tissue","volume":"2","author":"Springer","year":"1998","journal-title":"Brain Res. Brain Res. Protoc."},{"key":"10.1016\/j.neulet.2008.05.067_bib24","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1111\/j.1460-9568.2005.04438.x","article-title":"Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons","volume":"22","author":"Du","year":"2005","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neulet.2008.05.067_bib25","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/gerona\/62.9.943","article-title":"Glial cell-derived neurotrophic factor protects against proteasome inhibition-induced dopamine neuron degeneration by suppression of endoplasmic reticulum stress and caspase-3 activation","volume":"62","author":"Li","year":"2007","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"10.1016\/j.neulet.2008.05.067_bib26","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12264-007-0010-5","article-title":"Overexpression of lentivirus-mediated glial cell line-derived neurotrophic factor in bone marrow stromal cells and its neuroprotection for the PC12 cells damaged by lactacystin","volume":"23","author":"Su","year":"2007","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.neulet.2008.05.067_bib27","first-page":"371","article-title":"K252a is a selective inhibitor of the tyrosine protein kinase activity of the trk family of oncogenes and neurotrophin receptors","volume":"7","author":"Tapley","year":"1992","journal-title":"Oncogene"},{"key":"10.1016\/j.neulet.2008.05.067_bib28","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1096\/fj.05-5510fje","article-title":"Apomorphine-induced activation of dopamine receptors modulates FGF-2 expression in astrocytic cultures and promotes survival of dopaminergic neurons","volume":"20","author":"Li","year":"2006","journal-title":"FASEB J."},{"key":"10.1016\/j.neulet.2008.05.067_bib29","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1006\/bbrc.2000.2732","article-title":"Apomorphine up-regulates NGF and GDNF synthesis in cultured mouse astrocytes","volume":"272","author":"Ohta","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neulet.2008.05.067_bib30","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.neuroscience.2007.05.033","article-title":"Dopamine receptor activation reveals a novel, kynurenate-sensitive component of striatal N-methyl-d-aspartate neurotoxicity","volume":"148","author":"Poeggeler","year":"2007","journal-title":"Neuroscience"},{"key":"10.1016\/j.neulet.2008.05.067_bib31","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1046\/j.1471-4159.1996.66020501.x","article-title":"l-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress","volume":"66","author":"Han","year":"1996","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neulet.2008.05.067_bib32","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s007020070030","article-title":"Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection","volume":"107","author":"Le","year":"2000","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.neulet.2008.05.067_bib33","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.brainres.2004.09.014","article-title":"Direct evidence for expression of dopamine receptors in astrocytes from basal ganglia","volume":"1029","author":"Miyazaki","year":"2004","journal-title":"Brain Res."}],"container-title":["Neuroscience Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394008007106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394008007106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T20:08:23Z","timestamp":1759608503000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304394008007106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["S0304394008007106"],"URL":"https:\/\/doi.org\/10.1016\/j.neulet.2008.05.067","relation":{},"ISSN":["0304-3940"],"issn-type":[{"value":"0304-3940","type":"print"}],"subject":[],"published":{"date-parts":[[2008,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pramipexole has astrocyte-mediated neuroprotective effects against lactacystin toxicity","name":"articletitle","label":"Article Title"},{"value":"Neuroscience Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neulet.2008.05.067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}